BACKGROUND: Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment. METHODS: We studied associations of new-onset diabetes mellitus with hepatitis B virus and hepatitis C virus coinfections and antiretroviral therapy in participants in the Swiss HIV Cohort Study, using Poisson regression. RESULTS: A total of 123 of 6513 persons experienced diabetes mellitus during 27,798 person-years of follow-up (PYFU), resulting in an incidence of 4.4 cases per 1000 PYFU (95% confidence interval [CI], 3.7-5.3 cases per 1000 PYFU). An increased incidence rate ratio (IRR) was found for male subjects (IRR, 2.5; 95% CI, 1.5-4.2), older age (IRR for subjects >60 years old, 4.3; 95% CI, 2.3-8.2), black (IRR, 2.1; 95% CI, 1.1-4.0) and Asian (IRR, 4.9; 95% CI, 2.2-10.9) ethnicity, Centers for Disease Control and Prevention disease stage C (IRR, 1.6; 95% CI, 1.04-2.4), and obesity (IRR, 4.7; 95% CI, 3.1-7.0), but results for hepatitis C virus infection or active hepatitis B virus infection were inconclusive. Strong associations were found for current treatment with nucleoside reverse-transcriptase inhibitors (IRR, 2.22; 95% CI, 1.11-4.45), nucleoside reverse-transcriptase inhibitors plus protease inhibitors (IRR, 2.48; 95% CI, 1.42-4.31), and nucleoside reverse-transcriptase inhibitors plus protease inhibitors and nonnucleoside reverse-transcriptase inhibitors (IRR, 3.25; 95% CI, 1.59-6.67) but were not found for treatment with nucleoside reverse-transcriptase inhibitors plus nonnucleoside reverse-transcriptase inhibitors (IRR, 1.47; 95% CI, 0.77-2.82). CONCLUSIONS: In addition to traditional risk factors, current treatment with protease inhibitor- and nucleoside reverse-transcriptase inhibitor-containing regimens was associated with the risk of developing type 2 diabetes mellitus. Our study did not find a significant association between viral hepatitis infection and risk of incident diabetes.
BACKGROUND: Human immunodeficiency virus (HIV)-infectedpersons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment. METHODS: We studied associations of new-onset diabetes mellitus with hepatitis B virus and hepatitis C virus coinfections and antiretroviral therapy in participants in the Swiss HIV Cohort Study, using Poisson regression. RESULTS: A total of 123 of 6513 persons experienced diabetes mellitus during 27,798 person-years of follow-up (PYFU), resulting in an incidence of 4.4 cases per 1000 PYFU (95% confidence interval [CI], 3.7-5.3 cases per 1000 PYFU). An increased incidence rate ratio (IRR) was found for male subjects (IRR, 2.5; 95% CI, 1.5-4.2), older age (IRR for subjects >60 years old, 4.3; 95% CI, 2.3-8.2), black (IRR, 2.1; 95% CI, 1.1-4.0) and Asian (IRR, 4.9; 95% CI, 2.2-10.9) ethnicity, Centers for Disease Control and Prevention disease stage C (IRR, 1.6; 95% CI, 1.04-2.4), and obesity (IRR, 4.7; 95% CI, 3.1-7.0), but results for hepatitis C virus infection or active hepatitis B virus infection were inconclusive. Strong associations were found for current treatment with nucleoside reverse-transcriptase inhibitors (IRR, 2.22; 95% CI, 1.11-4.45), nucleoside reverse-transcriptase inhibitors plus protease inhibitors (IRR, 2.48; 95% CI, 1.42-4.31), and nucleoside reverse-transcriptase inhibitors plus protease inhibitors and nonnucleoside reverse-transcriptase inhibitors (IRR, 3.25; 95% CI, 1.59-6.67) but were not found for treatment with nucleoside reverse-transcriptase inhibitors plus nonnucleoside reverse-transcriptase inhibitors (IRR, 1.47; 95% CI, 0.77-2.82). CONCLUSIONS: In addition to traditional risk factors, current treatment with protease inhibitor- and nucleoside reverse-transcriptase inhibitor-containing regimens was associated with the risk of developing type 2 diabetes mellitus. Our study did not find a significant association between viral hepatitis infection and risk of incident diabetes.
Authors: Claude Béténé A Dooko; Stephane De Wit; Jacqueline Neuhaus; Adrian Palfreeman; Rosalie Pepe; James S Pankow; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2014-12-15 Impact factor: 3.731
Authors: Allison Longenberger; Jeong Youn Lim; Todd T Brown; Alison Abraham; Frank J Palella; Rita B Effros; Trevor Orchard; Maria Mori Brooks; Lawrence A Kingsley Journal: Future Virol Date: 2011-04 Impact factor: 1.831
Authors: Cleophas Chimbetete; Catrina Mugglin; Tinei Shamu; Bindu Kalesan; Barbara Bertisch; Matthias Egger; Olivia Keiser Journal: Trop Med Int Health Date: 2017-06-08 Impact factor: 2.622
Authors: Melissa A Frasco; Roksana Karim; David Van Den Berg; Richard M Watanabe; Kathryn Anastos; Mardge Cohen; Stephen J Gange; Deborah R Gustafson; Chenglong Liu; Phyllis C Tien; Wendy J Mack; Celeste L Pearce Journal: AIDS Date: 2014-07-31 Impact factor: 4.177
Authors: Karla I Galaviz; Michael F Schneider; Phyllis C Tien; C Christina Mehta; Ighovwerha Ofotokun; Jonathan Colasanti; Vincent C Marconi; Kartika Palar; Gina Wingood; Adaora A Adimora; Maria Alcaide; Mardge H Cohen; Deborah Gustafson; Roksana Karim; Deborah Konkle-Parker; Daniel Merenstein; Anjali Sharma; Mohammed K Ali Journal: AIDS Date: 2018-11-28 Impact factor: 4.177
Authors: Adeel A Butt; Kathleen McGinnis; Maria C Rodriguez-Barradas; Stephen Crystal; Michael Simberkoff; Matthew Bidwell Goetz; David Leaf; Amy C Justice Journal: AIDS Date: 2009-06-19 Impact factor: 4.177